Biomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis - discovery and implications.
about
Differences in immune responses against Leishmania induced by infection and by immunization with killed parasite antigen: implications for vaccine discoveryGenetically Modified Live Attenuated Leishmania donovani Parasites Induce Innate Immunity through Classical Activation of Macrophages That Direct the Th1 Response in Mice.Live Attenuated Leishmania donovani Centrin Knock Out Parasites Generate Non-inferior Protective Immune Response in Aged Mice against Visceral Leishmaniasis.DNA Microarray Detection of 18 Important Human Blood Protozoan SpeciesGene-deleted live-attenuated Trypanosoma cruzi parasites as vaccines to protect against Chagas disease.Gene deleted live attenuated Leishmania vaccine candidates against visceral leishmaniasis elicit pro-inflammatory cytokines response in human PBMCs.Whole genome sequencing of live attenuated Leishmania donovani parasites reveals novel biomarkers of attenuation and enables product characterization.Targeted Immunology for Prevention and Cure of VL.Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis.Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.Immunization with Live Attenuated Leishmania donovani Centrin-/- Parasites Is Efficacious in Asymptomatic Infection.Liposomal Elongation Factor-1α Triggers Effector CD4 and CD8 T Cells for Induction of Long-Lasting Protective Immunity against Visceral Leishmaniasis.Methods to Evaluate the Preclinical Safety and Immunogenicity of Genetically Modified Live-Attenuated Leishmania Parasite Vaccines.New Vaccine Formulations Containing a Modified Version of the Amastigote 2 Antigen and the Non-Virulent Trypanosoma cruzi CL-14 Strain Are Highly Antigenic and Protective against Leishmania infantum Challenge.
P2860
Q28077110-9D72CE98-7719-409B-B471-AB8FCDFB8E2EQ36053499-2BFC6741-5C5B-47B8-98E4-FDC0691D64E6Q36118527-FA11218E-3876-49A2-B879-575D2987432EQ36211811-938FA74D-3790-4791-B37A-B8F77DC82DDCQ38286350-9F3880D8-C0C9-48F1-BC14-624DDF82E515Q40541534-C0159C94-4A16-46E7-98DA-6EBB7C912C5DQ40957138-3B947A34-12A5-4A19-AAF0-93FE3A463FBAQ41558777-8135059C-8DD8-4D56-9085-DE9EACBD389AQ47137387-6F6FE681-DF64-406C-8DF9-19F16DF45EC4Q47548487-B3AFA9AE-7AC7-4D63-91BC-2975585F022AQ48546496-35E60F64-3F46-4643-BBCC-C997B06ED695Q49210114-503E77BA-2072-4123-B304-5869B697F4BDQ51372327-A5325090-2442-44E5-B2BA-7BD6523217A4Q52723035-F81054A9-7B92-4FEE-BBC2-72965B15B579
P2860
Biomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis - discovery and implications.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Biomarkers of safety and immun ...... - discovery and implications.
@ast
Biomarkers of safety and immun ...... - discovery and implications.
@en
type
label
Biomarkers of safety and immun ...... - discovery and implications.
@ast
Biomarkers of safety and immun ...... - discovery and implications.
@en
prefLabel
Biomarkers of safety and immun ...... - discovery and implications.
@ast
Biomarkers of safety and immun ...... - discovery and implications.
@en
P2093
P2860
P921
P356
P1476
Biomarkers of safety and immun ...... - discovery and implications.
@en
P2093
Angamuthu Selvapandiyan
Hira L Nakhasi
Kumar Avishek
Ranadhir Dey
Sreenivas Gannavaram
P2860
P356
10.3389/FIMMU.2014.00241
P577
2014-05-23T00:00:00Z